Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

J Mulvey J, Magro C, Chadburn A. Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy. Blood Cells Mol Dis. 2018;69:38-42.

Schwartz Z, Bowe RB, Coleman M, Magro CM. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. Ann Diagn Pathol. 2018;37:57-61.

Magro CM, Kazi N, Sisinger AE. Primary cutaneous histiocytic sarcoma: A report of five cases with primary cutaneous involvement and review of the literature. Ann Diagn Pathol. 2018;32:56-62.

Huse HK, Miller SA, Chandrasekaran S, Hindler JA, Lawhon SD, Bemis DA, et al. Evaluation of Oxacillin and Cefoxitin Disk Diffusion and MIC Breakpoints Established by the Clinical and Laboratory Standards Institute for Detection of -Mediated Oxacillin Resistance in Staphylococcus schleiferi. J Clin Microbiol. 2018;56(2).

Ellis L, Loda M. LSD1: A single target to combat lineage plasticity in lethal prostate cancer. Proc Natl Acad Sci U S A. 2018;115(18):4530-4531.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, et al. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precis Oncol. 2018;2018.

Li W, Xia S, Aronova A, Min IM, Verma A, Scognamiglio T, et al. CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules. J Surg Oncol. 2018;118(6):1042-1049.

Ko H-, Berk M, Chung Y-, Willard B, Bareja R, Rubin M, et al. Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer. Cell Rep. 2018;22(3):809-819.

Huang J, Diaz-Meco MT, Moscat J. The macroenviromental control of cancer metabolism by p62. Cell Cycle. 2018;17(17):2110-2121.

Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, et al. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018;59(12):2829-2835.